JP2011528352A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011528352A5 JP2011528352A5 JP2011518733A JP2011518733A JP2011528352A5 JP 2011528352 A5 JP2011528352 A5 JP 2011528352A5 JP 2011518733 A JP2011518733 A JP 2011518733A JP 2011518733 A JP2011518733 A JP 2011518733A JP 2011528352 A5 JP2011528352 A5 JP 2011528352A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic composition
- secreted protein
- isolated
- purified
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002987 choroid plexus Anatomy 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 21
- 238000000034 method Methods 0.000 claims 17
- 102000004169 proteins and genes Human genes 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 230000001225 therapeutic effect Effects 0.000 claims 14
- 239000003636 conditioned culture medium Substances 0.000 claims 8
- -1 PDGF Proteins 0.000 claims 6
- 206010052428 Wound Diseases 0.000 claims 6
- 208000027418 Wounds and injury Diseases 0.000 claims 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims 3
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims 3
- 102100031168 CCN family member 2 Human genes 0.000 claims 3
- 108050006947 CXC Chemokine Proteins 0.000 claims 3
- 102000019388 CXC chemokine Human genes 0.000 claims 3
- 102000015833 Cystatin Human genes 0.000 claims 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 3
- 102000016359 Fibronectins Human genes 0.000 claims 3
- 108010067306 Fibronectins Proteins 0.000 claims 3
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 claims 3
- 101001135738 Homo sapiens Parathyroid hormone-related protein Proteins 0.000 claims 3
- 108091058560 IL8 Proteins 0.000 claims 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 3
- 102000004890 Interleukin-8 Human genes 0.000 claims 3
- 108090001007 Interleukin-8 Proteins 0.000 claims 3
- 102000007547 Laminin Human genes 0.000 claims 3
- 108010085895 Laminin Proteins 0.000 claims 3
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 3
- 102100036899 Parathyroid hormone-related protein Human genes 0.000 claims 3
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 claims 3
- 108010071690 Prealbumin Proteins 0.000 claims 3
- 102000005157 Somatostatin Human genes 0.000 claims 3
- 108010056088 Somatostatin Proteins 0.000 claims 3
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims 3
- 102400001320 Transforming growth factor alpha Human genes 0.000 claims 3
- 102000009190 Transthyretin Human genes 0.000 claims 3
- 102000009137 Tropomodulin-3 Human genes 0.000 claims 3
- 108050000002 Tropomodulin-3 Proteins 0.000 claims 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 3
- 108010001122 alpha(2)-microglobulin Proteins 0.000 claims 3
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 3
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 3
- 108050004038 cystatin Proteins 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 210000002744 extracellular matrix Anatomy 0.000 claims 3
- 108090000102 pigment epithelium-derived factor Proteins 0.000 claims 3
- 229930002330 retinoic acid Natural products 0.000 claims 3
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 3
- 229960000553 somatostatin Drugs 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 229960001727 tretinoin Drugs 0.000 claims 3
- 230000029663 wound healing Effects 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- 206010072170 Skin wound Diseases 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000002537 cosmetic Substances 0.000 claims 2
- 230000035876 healing Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000004983 pleiotropic effect Effects 0.000 claims 2
- 208000025978 Athletic injury Diseases 0.000 claims 1
- 208000034656 Contusions Diseases 0.000 claims 1
- 206010056340 Diabetic ulcer Diseases 0.000 claims 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 108010076282 Factor IX Proteins 0.000 claims 1
- 206010018852 Haematoma Diseases 0.000 claims 1
- 206010019909 Hernia Diseases 0.000 claims 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 1
- 206010041738 Sports injury Diseases 0.000 claims 1
- 208000002847 Surgical Wound Diseases 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 230000002730 additional effect Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000009519 contusion Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 229960001810 meprednisone Drugs 0.000 claims 1
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 210000002435 tendon Anatomy 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13502608P | 2008-07-15 | 2008-07-15 | |
| US61/135,026 | 2008-07-15 | ||
| PCT/US2009/004129 WO2010008573A2 (en) | 2008-07-15 | 2009-07-15 | Wound healing |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016002681A Division JP6309033B2 (ja) | 2008-07-15 | 2016-01-08 | 創傷の治癒 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011528352A JP2011528352A (ja) | 2011-11-17 |
| JP2011528352A5 true JP2011528352A5 (enExample) | 2012-09-13 |
Family
ID=41550919
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011518733A Pending JP2011528352A (ja) | 2008-07-15 | 2009-07-15 | 創傷の治癒 |
| JP2016002681A Active JP6309033B2 (ja) | 2008-07-15 | 2016-01-08 | 創傷の治癒 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016002681A Active JP6309033B2 (ja) | 2008-07-15 | 2016-01-08 | 創傷の治癒 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20110177025A1 (enExample) |
| EP (1) | EP2318034B1 (enExample) |
| JP (2) | JP2011528352A (enExample) |
| AU (3) | AU2009271598A1 (enExample) |
| NZ (1) | NZ591037A (enExample) |
| WO (1) | WO2010008573A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2751679C (en) * | 2009-02-06 | 2018-02-27 | Women & Infants' Hospital Of Rhode Island | Compositions for treating preeclampsia-type disorders of pregnancy comprising transthyretin |
| WO2012126369A1 (zh) * | 2011-03-22 | 2012-09-27 | 北京三诺佳邑生物技术有限责任公司 | 核苷酸、包括其的重组载体、细胞、组合物及它们的应用 |
| US20130123647A1 (en) | 2011-05-03 | 2013-05-16 | The Research Foundation Of State University Of New York | Methods Useful in Optimizing the Treatment of Neuropathies and Targeting Tissues with Cosmetic Botulinum Injections |
| KR20180128097A (ko) * | 2012-02-10 | 2018-11-30 | 재패닉 코포레이션 | 비 인간 줄기세포의 배양 상등액을 원료로 하는 화장품 또는 피부 재생 촉진제, 및 단백질의 이온 도입 방법 |
| EP2687224A1 (en) * | 2012-07-19 | 2014-01-22 | Tissue Med Biosciences Forschungs- und Entwicklungsgesellschaft mbH | Medicament for wound treatment |
| US20140088402A1 (en) | 2012-09-25 | 2014-03-27 | Innovative Therapies, Inc. | Wound measurement on smart phones |
| CN106906180A (zh) * | 2016-12-28 | 2017-06-30 | 里程 | 一种具有生物活化作用的复合添加剂及其制备方法和用途 |
| CN111050763B (zh) | 2017-12-26 | 2024-10-11 | 福冈大太朗 | 用于増毛、头皮或皮肤的改质、创伤治愈、骨形成促进或毛发的改质的药物组合物 |
| CN113274538B (zh) * | 2021-05-28 | 2022-09-06 | 中国科学院过程工程研究所 | 一种具有创面主动修复功能的bFGF缓释纳米敷料及其制备方法和应用 |
| CN114381421B (zh) * | 2022-02-09 | 2023-08-15 | 河北医科大学 | 溶菌酶诱导的小鼠血管平滑肌细胞炎症模型及其建立方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4021A (en) * | 1845-05-01 | Isaac l | ||
| US8011A (en) * | 1851-04-01 | Improvement in blasti ng rocks | ||
| US20020127594A1 (en) * | 2000-06-22 | 2002-09-12 | Gearing David P. | Don-1 gene and polypeptides and uses therefor |
| US20040213768A1 (en) * | 1999-04-30 | 2004-10-28 | Elliott Robert Bartlett | Preparation for biotransplantation and xenotransplantion and uses thereof |
| AU4440000A (en) * | 1999-04-30 | 2000-11-17 | Diatranz Limited | Xenotransplant for cns therapy |
| US20050265977A1 (en) * | 1999-04-30 | 2005-12-01 | Elliott Robert B | Xenotransplant for CNS therapy |
| EP1575524A4 (en) * | 2002-02-08 | 2008-11-05 | Univ South Florida | PROLIFERED CELL LINES AND ITS USE |
| US20040009915A1 (en) * | 2002-03-06 | 2004-01-15 | Han Chang | Polynucleotides encoding a novel intracellular chloride channel-related polypeptide |
| NZ536009A (en) * | 2005-04-18 | 2007-01-26 | Neurotrophincell Pty Ltd | Choroid plexus preparation and uses thereof |
| NZ540597A (en) * | 2005-06-08 | 2007-02-23 | Neurotrophincell Pty Ltd | A method for preventing the onset of type I diabetes comprising administering an implantable composition comprising living choroid plexus cells |
| WO2007028053A2 (en) * | 2005-09-02 | 2007-03-08 | X-Cell Medical Incorporated | Methods of treating and preventing cardiac disorders |
| CA2580907A1 (en) * | 2006-11-21 | 2008-05-21 | The Bionic Ear Institute | Choroid plexus cell implantation to prevent and/or treat hearing loss |
| ES2324192B1 (es) * | 2008-01-30 | 2010-06-17 | PUIG BEAUTY & FASHION GROUP, S.L. | Derivados peptidicos utiles en el tratamiento, cuidado o limpieza de la piel, mucosa, cuero cabelludo o uñas. |
-
2009
- 2009-07-15 NZ NZ591037A patent/NZ591037A/xx unknown
- 2009-07-15 JP JP2011518733A patent/JP2011528352A/ja active Pending
- 2009-07-15 EP EP09798310.0A patent/EP2318034B1/en active Active
- 2009-07-15 WO PCT/US2009/004129 patent/WO2010008573A2/en not_active Ceased
- 2009-07-15 US US13/054,428 patent/US20110177025A1/en not_active Abandoned
- 2009-07-15 AU AU2009271598A patent/AU2009271598A1/en not_active Abandoned
-
2015
- 2015-09-10 US US14/850,755 patent/US20180008644A1/en not_active Abandoned
-
2016
- 2016-01-08 JP JP2016002681A patent/JP6309033B2/ja active Active
- 2016-05-05 AU AU2016202913A patent/AU2016202913A1/en not_active Abandoned
-
2018
- 2018-03-16 AU AU2018201925A patent/AU2018201925C1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH05506673A (ja) | 迅速な創傷の治癒を促進するためのｇｍ―ｃｓｆ及びｇ―ｃｓｆの使用 | |
| Brown et al. | Enhancement of wound healing by topical treatment with epidermal growth factor | |
| RU2712635C1 (ru) | Композиции для содействия заживлению кожных язв и ран | |
| US12005084B2 (en) | Composition derived from mammalian umbilical cord and Whartons jelly for use in therapeutic and regenerative applications | |
| JP6309033B2 (ja) | 創傷の治癒 | |
| KR20080100425A (ko) | 조절된 혈액 조성물 및 이의 생산 방법 | |
| KR20160113955A (ko) | 모발 성장 촉진용 염기성 섬유모세포 생장인자 조성물 및 그 제조 방법 | |
| US20100222253A1 (en) | Methods for extracting platelets and compositions obtained therefrom | |
| US11813309B2 (en) | Method of alleviating chronic wounds | |
| JP2002530353A5 (enExample) | ||
| Louzada et al. | Granulocyte-colony stimulating factor treatment of chronic myocardial infarction | |
| Mzezewa et al. | A prospective double blind randomized study comparing the need for blood transfusion with terlipressin or a placebo during early excision and grafting of burns | |
| JP4790195B2 (ja) | 組織再生剤 | |
| CN106420779A (zh) | 一种促进伤口愈合的组合物 | |
| CN1250287C (zh) | 一种重组腺病毒在脑缺血、创伤修复和组织粘连治疗中的应用 | |
| US20230398195A1 (en) | Composition derived from mammalian umbilical cord and whartons jelly for use in therapeutic and regenerative applications | |
| CN120661514B (zh) | Jak抑制剂新应用及促进皮肤牵张再生的药物 | |
| WO2008073653A2 (en) | Il- 17b for use in wound healing | |
| CN1956705A (zh) | 用于治疗局部细菌感染和细菌性相关疾病的集落刺激因子组合物 | |
| ES2980536T3 (es) | Catalizador para la regeneración de tejidos y método relacionado para fabricarlo | |
| US20240123017A1 (en) | Use of Bletilla formosana (Hayata) Schltr. Extract for The Manufacture of A Pharmaceutical Composition For Promoting Chronic Wound Healing | |
| Cheng et al. | Effects of the Zhikang capsule on healing of the flap after radical breast cancer surgery | |
| CN120168610A (zh) | 一种白细胞介素-13在促进肌肉损伤后修复中的应用 | |
| CN113797316A (zh) | 用于修复组织损伤的组合物及其制备方法和应用 | |
| CN116196394A (zh) | 重组人Matrilin-3蛋白在制备治疗脑血管疾病的药物中的应用 |